- 4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call TranscriptFeb 05, 2024
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call TranscriptNov 01, 2023
- 4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- 4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- 4D Molecular Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call TranscriptJun 07, 2023
- 4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- 4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- 4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call TranscriptApr 27, 2023
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call TranscriptFeb 22, 2023
- 4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call TranscriptNov 14, 2022
- 4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call TranscriptNov 03, 2022
- 4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- 4D Molecular Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call TranscriptOct 25, 2021
4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and really pleased to have the 4D Molecular Therapeutics team with us. So maybe to start here, David. I'd have you just introduce the company kind of the situation that's played out through IPO until now with regard to the directed evolution platform, the disease verticals and where we've seen the progress play out across the programs to date.
Perfect. Well, thanks for having us here today. We're pleased to be here. I'm Dave Kirn, Co-Founder and CEO and this is [Julian Pay] , our Head of Investor Relations. So we're thrilled to be here. So 4D Molecular Therapeutics is a next-generation gene therapy company that's built on the power of the directed evolution platform to invent customized AV delivery vectors for any tissue in the body essentially.
And so what this allows us to do is have best
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)